Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study

Background Glucagon-like peptide-1 receptor agonists may influence systemic inflammation beyond their glucose-lowering effects, but direct comparative evidence against other incretin-based therapies remains limited. Methods We conducted a retrospective active-comparator, new-user cohort study using routinely collected electronic health-record data from the Clinical Center of the University of Debrecen, Hungary. Patients with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor between January 2001 and December 2024 after a 12-month washout were included. Baseline markers were summarized during months −12 to −1 and follow-up markers during months 4–12. The follow-up window was selected to reduce the influence of very early post-initiation testing while allowing assessment of a sustained biomarker difference. Propensity-score overlap weighting was used to balance demographic, metabolic, renal, cardiovascular, medication, and healthcare-observation characteristics. Results The propensity-score cohort included 1,973 patients, including 1,322 glucagon-like peptide-1 receptor agonist and 651 dipeptidyl peptidase-4 inhibitor initiators; 838 had paired C-reactive protein measurements. The adjusted geometric mean ratio for follow-up C-reactive protein was 0.80 (95% confidence interval, 0.66–0.97; P = 0.024). The neutrophil-to-lymphocyte ratio was also lower (adjusted ratio, 0.92; 95% confidence interval, 0.87–0.97; P = 0.003; q=0.007), whereas platelet count was higher by 12.12×10 9 /L (95% confidence interval, 4.65–19.59; P = 0.001; q=0.007). The C-reactive protein estimate remained similar after upper-tail winsorization, propensity-score re-estimation within the paired-CRP cohort, and patient-level bootstrap re-estimation of the propensity score. Restriction to patients with baseline CRP <10 mg/L yielded a directionally similar but less precise estimate, whereas stabilized inverse-probability-of-treatment weighting did not statistically support the association. Conclusion GLP-1 receptor agonist initiation was associated with lower follow-up CRP and NLR than DPP-4 inhibitor initiation among patients with available paired measurements in the propensity-score overlap population. However, the CRP association was attenuated in the 12-month survivor-restricted analysis and varied across other sensitivity analyses. Residual confounding by adiposity, treatment-associated weight changes, and selection related to survival and laboratory availability limit causal interpretation. The findings should be considered exploratory comparative biomarker associations rather than evidence of a direct or weight-independent anti-inflammatory effect.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-16
DOI
https://doi.org/10.3389/fendo.2026.1959709
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study

Battamir Ulambayar, Amr Sayed Ghanem, Ferenc Sztanek, Attila Nagy et al.
3 links
Frontiers in Endocrinology
Diabetes Treatment and Management
article

Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study

Battamir Ulambayar, Amr Sayed Ghanem, Ferenc Sztanek, Attila Nagy, Vivien Jendrek
article en

Abstract

Background Glucagon-like peptide-1 receptor agonists may influence systemic inflammation beyond their glucose-lowering effects, but direct comparative evidence against other incretin-based therapies remains limited. Methods We conducted a retrospective active-comparator, new-user cohort study using routinely collected electronic health-record data from the Clinical Center of the University of Debrecen, Hungary. Patients with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor between January 2001 and December 2024 after a 12-month washout were included. Baseline markers were summarized during months −12 to −1 and follow-up markers during months 4–12. The follow-up window was selected to reduce the influence of very early post-initiation testing while allowing assessment of a sustained biomarker difference. Propensity-score overlap weighting was used to balance demographic, metabolic, renal, cardiovascular, medication, and healthcare-observation characteristics. Results The propensity-score cohort included 1,973 patients, including 1,322 glucagon-like peptide-1 receptor agonist and 651 dipeptidyl peptidase-4 inhibitor initiators; 838 had paired C-reactive protein measurements. The adjusted geometric mean ratio for follow-up C-reactive protein was 0.80 (95% confidence interval, 0.66–0.97; P = 0.024). The neutrophil-to-lymphocyte ratio was also lower (adjusted ratio, 0.92; 95% confidence interval, 0.87–0.97; P = 0.003; q=0.007), whereas platelet count was higher by 12.12×10 9 /L (95% confidence interval, 4.65–19.59; P = 0.001; q=0.007). The C-reactive protein estimate remained similar after upper-tail winsorization, propensity-score re-estimation within the paired-CRP cohort, and patient-level bootstrap re-estimation of the propensity score. Restriction to patients with baseline CRP <10 mg/L yielded a directionally similar but less precise estimate, whereas stabilized inverse-probability-of-treatment weighting did not statistically support the association. Conclusion GLP-1 receptor agonist initiation was associated with lower follow-up CRP and NLR than DPP-4 inhibitor initiation among patients with available paired measurements in the propensity-score overlap population. However, the CRP association was attenuated in the 12-month survivor-restricted analysis and varied across other sensitivity analyses. Residual confounding by adiposity, treatment-associated weight changes, and selection related to survival and laboratory availability limit causal interpretation. The findings should be considered exploratory comparative biomarker associations rather than evidence of a direct or weight-independent anti-inflammatory effect.

Frontiers in EndocrinologyVol. 17
University of Debrecen (HU)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon